Evidence map›Paper›PMID 28054119›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2017

Nitric oxide mediates prolyl hydroxylase 3 expression in mesangial cells and in glomerulonephritis.

Ahmed Aglan, Sebastian Longen, Nathalie Dehne, Yvette Köhler, Mohamed Hassan, Martina Beck, Claudia Tredup, Meike Boosen, Tzung-Harn Louise Hsieh, Liliana Schaefer and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Mesangial renal disease, oxygen sensing, and prolyl hydroxylase.Journal of molecular medicine (Berlin, Germany) · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Ahmed AglanPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
Sebastian LongenPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
Nathalie DehneInstitut für Biochemie, Pathobiochemie, Goethe Universität, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
Yvette KöhlerPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
Mohamed HassanPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
Martina BeckPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
Claudia TredupPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
Meike BoosenPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
Tzung-Harn Louise HsiehPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
Liliana SchaeferPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
Karl-Friedrich BeckPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany. k.f.beck@em.uni-frankfurt.de.
Josef PfeilschifterPharmazentrum Frankfurt/ZAFES, Goethe Universität, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, D 60590, Frankfurt am Main, Germany.
University Hospital Frankfurt · DEGoethe University Frankfurt · DEAl-Azhar University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal mesangial cells are regarded as main players in glomerular inflammatory diseases. To investigate a possible crosstalk between inflammatory and hypoxia-driven signaling processes, we stimulated cultured mouse mesangial cells with different inflammatory agents and analyzed the expression of prolyl hydroxylase domain containing proteins (PHDs), the main regulators of hypoxia-inducible factor (HIF) stability. Administration of IL-1β (1 nM) and TNF-α (1 nM), a combination further referred to as cytokine mix (CM), resulted in a fivefold increase in PHD3 but not PHD1 and PHD2 mRNA expression compared to untreated controls. In contrast, a combination of IL-1β, TNF-α with lipopolysaccharide (10 μg/ml), and interferon-γ (20 ng/ml) designated as CM+ showed a high (60-fold) induction of PHD3 and a moderate (twofold) induction of PHD2 mRNA expression. Interestingly, CM+ but not CM induced the expression of inducible NO synthase and endogenously produced NO was responsible for the immense induction of PHD3 in mesangial cells treated with CM+. We found that CM+ affected PHD3 expression mainly via the NO/HIF axis, whereas PHD3 regulation by CM occurred in a NF-κB-dependent manner. In turn, silencing of PHD3 expression resulted in a decrease in the mRNA expression of ICAM-1, MIP-2, MCP-1, and CXCL-10, which are under control of NF-κB. In a rat model of mesangio-proliferative glomerulonephritis, PHD3 mRNA and protein expression was markedly induced and this effect was nearly abolished when rats were treated with the iNOS-specific inhibitor L-NIL, thus confirming our findings also in vivo. KEY MESSAGE: PHD3 expression induced by cytokines is NF-κB dependent in mesangial cells. Endogenously produced NO further augments PHD3 expression via HIF-1α. PHD3 expression is induced by NO in anti-Thy-1 glomerulonephritis.

Indexed as

Up-RegulationAnimalsCells, CulturedGlomerulonephritisHumansInterleukin-1betaMesangial CellsMiceMice, Inbred C57BLNF-kappa BNitric OxideProcollagen-Proline DioxygenaseRNA, MessengerTumor Necrosis Factor-alphaInterleukin-1betaNF-kappa BNitric OxideProcollagen-Proline Dioxygenaseproline, 2-oxoglutarate 3-dioxygenaseRNA, MessengerTumor Necrosis Factor-alphaMesangial cellsNitric oxideProlyl hydroxylase domain containing protein 3

Identifiers

PMID28054119
OpenAlexW2569424211

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.